Biogen Inc (BIIB)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	4,547,200	—	—	—	6,788,200	—	—	—	6,567,300	—	—	—	7,567,300	—	—	—	7,500,000	—	—	—
Total stockholders’ equity	US$ in thousands	16,716,000	16,358,900	15,889,100	15,213,000	14,799,400	14,483,800	14,466,900	13,796,600	13,397,900	12,775,500	11,872,500	11,242,300	10,896,200	10,429,900	10,751,900	10,682,200	10,700,300	10,758,500	11,308,700	12,546,900
Debt-to-equity ratio		0.27	0.00	0.00	0.00	0.46	0.00	0.00	0.00	0.49	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.70	0.00	0.00	0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $4,547,200K ÷ $16,716,000K
= 0.27

The debt-to-equity ratio of Biogen Inc has shown fluctuations in the recent periods. As of December 31, 2020, the ratio stood at 0.70, indicating the company had a higher level of debt relative to equity at that point. Subsequently, the ratio decreased significantly to 0.49 by December 31, 2022, suggesting a reduction in the proportion of debt in the company's capital structure.

From 2020 to 2022, the company took steps to possibly pay down debt or increase equity, leading to a decreased reliance on debt financing. However, it is noteworthy that the ratio increased slightly to 0.46 by December 31, 2023, indicating a slight uptick in debt relative to equity.

Overall, the debt-to-equity ratio for Biogen Inc over the reviewed periods suggests a pattern of managing debt levels and maintaining a balanced capital structure. Investors and stakeholders may monitor this ratio to assess the company's financial leverage and risk profile.